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Abstract
The primitive neuroectodermal tumor (PNET) of the kidney is an extremely rare neoplasm, the diagnosis of which mainly depends upon his-
topathology, immunohistochemistry (IHC), and cytogenetics. A handful of cases reported in the literature mention about aggressive features 
of this neoplasm. The purpose of our study was to review our experience in not only the diagnosis and management of the patients with renal 
PNET but also to highlight its propensity to involve inferior vena cava (IVC) and also present a rare occurrence of Ewing’s sarcoma (ES)/PNET 
of the renal pelvis.
The clinical, operative, and histopathology records of four patients of renal PNET treated between January 2017 and December 2019 were 
reviewed and data analyzed concerning the available literature. Out of the four patients treated, two had level III and IV IVC thrombus, and one 
had dense desmoplastic adhesions with the IVC wall. One of the cases had a rare presentation of ES/PNET of the renal pelvis. All patients were 
managed surgically, while only one patient received adjuvant chemotherapy and following up with remission for the last 2 years and 4 months. 
On IHC, cluster of differentiation-99 (CD-99) was positive in all patients, and three were positive for Friend leukemia integration-1. PNET of 
the kidney is primarily an immunohistopathological diagnosis. This neoplasm has an increased propensity for the local invasion of surrounding 
structures. A multimodality approach with surgery, chemotherapy, and radiotherapy could offer better outcomes, although the prognosis of 
these tumors remains poor.
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The primitive neuroectodermal tumor (PNET) includes 
a group of small round cell tumors (RCT) of universal 
location and apparent neuroectodermal origin, presenting 
as a disease of bone and soft tissue (1). In a rare situation, 
PNET has been found in the genitourinary system such as 
kidney (2), bladder (3), prostate (4), testis, epididymis, ovary, 
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involving inferior vena cava (IVC) and one out of these pre-
senting as a renal pelvis tumor.
Case series
From January 2017 to December 2019, four cases of renal 
PNET were managed in the department of urology and renal 
transplantation at our tertiary care institute. Consent from 
study participants and approval of the institutional ethics 
committee were taken to review the case records. The sum-
mary of clinical presentation, and treatment and follow-up 
are described in Table 1.
and uterus (5). Very rarely, they can occur as a primary renal 
tumor (6). Renal PNET exhibits highly aggressive biologi-
cal behavior with poor prognosis, and until now <100 cases 
have been reported (7). Generally, renal PNET affects young 
adults at a median age of 28 years and has a male predom-
inance of 3:1 (8). Histopathology and immunohistochemis-
try (IHC) showing positivity for cluster of differentiation-99 
(CD-99) and Friend leukemia integration-1 (FLI-1), sup-
ported by cytogenetic studies, play a significant role in the 
diagnosis of PNET (9).
We herein report our experience of clinical presentation, 
imaging, and management of four cases of renal PNET 
Table 1: Summary of clinical presentation, and treatment and follow-up of four cases of renal PNET.
Parameters Case 1 Case 2 Case 3 Case 4
Age/sex 19/Male 30/Female 62/Female 56/Female
Presentation M, P P, M, W, H W P, F
Performance scale (ECOG) 1 2 2 2
Laterality Right Left Right Right
Extent L LA LA L
Provisional diagnosis RCC Renal oncocytoma+ 
? coexistent RCC
RCC TCC
Surgery RN+LND RN+LND+IVCT RN+LND+IVCT RN+LND+IVC 






































Adjuvant therapy Chemotherapy 
VAC/IE -17 cycles, 
G-CSF
No No No
Survival in months 2 years and  




8 months Lost to follow-up
PNET, primitive neuroectodermal tumor; ECOG, Eastern Cooperative Oncology Group; IHC, immunohistochemistry; G-CSF,  
granulocyte-colony stimulating factor; LA, locally advanced; RN, radical nephrectomy; VAC/IE, vincristine, adriamycin, cyclophosphamide/
ifosfamide, etoposide; CG, chromogranin; CK, cytokeratin; Des, Desmin; NSE, neuron-specific enolase; SNP, synaptophysin; WT-1, Wilms 
tumor.
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In our study, the median age was 43 years (age range 19–62 
years). The most common complaint was abdominal pain in 
three (75%) cases, abdominal mass in two (50%) cases, weight 
loss in two (50%) cases, hematuria in 1 (25%) case, and fever in 1 
(25%) case. None of the patients had evidence of metastasis.
Three of the cases had nonspecific imaging findings and 
were thought to be Renal cell carcinoma (RCC) provisionally 
(Figures 1a, b, and c). In contrast, another patient was diag-
nosed with an upper tract transitional cell carcinoma (TCC). 
Magnetic resonance (MR) urography of this case (Figure 1d) 
showed a heterogenous well-defined mass lesion of 8 × 6-cm 
size predominantly iso-intense in T2 and iso to hypo-intense 
in T1 with restricted diffusion, involving renal pelvis of the 
right kidney and anteriorly compressing IVC with focal loss 
of the fat plane. Gross hydronephrosis was noted with thin-
ning of parenchyma along with deranged renal parameters. 
All cases underwent radical nephrectomy and lymph node 
dissection. The median size of the tumor was 14 cm (range 
12–25.5 cm). Two patients underwent IVC thrombectomy. 
One patient, diagnosed with intrapericardial IVC thrombus, 
required cardiopulmonary bypass but had significant intra-
operative blood loss because of extensive neovascularization. 
(a) (b)
(c) (d)
Figure 1: (a) CECT abdomen and pelvis transverse section (Case 1) showing right renal mass, compressing medially the right 
renal vein, ureter, and IVC with sectoral contact of about 180° with no apparent tumor thrombosis. (b) CECT thorax and 
coronal abdomen section (Case 2) revealed that left renal mass lesion with enhancing tumor thrombus extending up to the 
supradiaphragmatic IVC. (c) Plain MRI abdomen coronal section (Case 3) showing well-defined lobulated mass lesion with 
IVC thrombosis extending into the suprarenal IVC, below the diaphragm. (d) MR urography transverse section (Case 4) show-
ing a well-defined mass of size 8 × 6 cm involving the renal pelvis, compressing IVC anteriorly. IVC, inferior vena cava; CECT, 
 contrast-enhanced computed tomography.
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Discussion
Seemayer and colleagues first reported ES/PNET of the 
kidney in 1975 (2). Renal localization of PNET is very rare 
(1). Owing to rarity, a limited number of cases have been 
reported in the literature until now, and hence the proper 
analysis of prognosis of renal PNET is not available.
Although PNET tumors are mostly seen in adolescents 
and young adults, these can present in any age group. In 
our experience, the median age is 43 years, which is higher 
compared to other studies. Contrary to the literature, men-
to-women ratio in our experience was the lowest one. The 
presenting symptoms of renal PNET are nonspecific, includ-
ing flank pain, abdominal mass, hematuria, and other symp-
toms related to genitourinary infections (9). A retrospective 
study done by Sun et al. showed most patients (87%) having 
renal PNET on the left side, but our study and case series 
conducted by Narayanan et al. revealed it to be on the right 
kidney in most of the patients (10,11).
The imaging characteristics of renal PNET are generally 
nonspecific. They can masquerade as any other tumor of 
renal origins such as RCC, Wilms tumor, neuroblastoma, 
lymphoma, and desmoplastic small RCT.
In 2014, Liu et al. reported the world’s first renal pelvis 
ES/PNET (12). To our knowledge, very few cases of the 
renal pelvis, ES/PNET tumor are reported in the literature 
to date. No known specific imaging findings are available 
for renal pelvis ES/PNET mimicking as renal pelvis TCC. 
In our study, one case presented as the tumor of the renal 
She developed disseminated intravascular coagulation (DIC) 
postoperatively and succumbed to the disease.
Intraoperatively, in the case of renal pelvis tumor, dense 
desmoplastic adhesions with IVC were found along the 
entire length of the mass (Figures 2a and b). She underwent 
radical nephroureterectomy, lymph node dissection, and IVC 
cuff excision with primary repair.
Histopathology and IHC study was done for all cases. 
It revealed tumor cells arranged in sheets. These comprise 
small, round-to-oval cells with a hyperchromatic nucleus 
and mild-to-moderate pale staining cytoplasm. At places, 
the tumor cells were arranged in pseudo rosettes (Figure 3a). 
On IHC, we have consistently found CD-99 in all cases (Fig-
ure 3b), FLI-1 in three (75%) cases (Figure 3c), and vimen-
tin in one (25%) case. Provisionally diagnosed case of upper 
tract TCC was confirmed to be ES/PNET of renal pelvis 
origin along with the presence of infiltration of the ureter 
 (Figures 3a, b, and c).
After discussion of institutional tumor board, one patient 
agreed to receive adjuvant chemotherapy with Vincristine, 
Adriamycin, Cyclophosphamide, Etoposide, and Ifosfamide 
(VAC/IE) of total 17 cycles as per Ewing’s family of tumors 
(EFT) 2001 protocol followed by granulocyte colony-stim-
ulating factor (G-CSF) to avoid febrile neutropenia. He is 
on regular follow-up with a relapse-free interval of 2 years 
and 4 months. None of the patients received adjuvant radio-
therapy. One patient was lost to follow-up, while another 
patient refused adjuvant therapy and died with relapse after 
8 months of surgery.
(a) (b)
Figure 2: Intra-operative pictures of Case 4. (a) Showing tumor specimen of size 12.5 × 8 × 4 cm involving renal pelvis with 
grossly hydronephrotic right kidney. (b) Showing post-nephroureterectomy right renal bed with repaired IVC after excising 
involved cuff. IVC, inferior vena cava.
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pelvis along with gross hydronephrosis (Figure 1d), which 
was subsequently confirmed as ES/PNET (Figures 3a, b, 
and c). The differential diagnosis of renal pelvis ES/PNET 
includes urothelial cancer, amyloidosis, fibroepithelial polyp, 
other soft-tissue sarcomas, and lymphoma (13). Preoperative 
diagnosis is difficult based on imaging. Hence, computed 
tomography (CT)-guided fine-needle aspiration biopsy and 
ureteroscopic biopsy are considered for early diagnosis.
In our series, three out of four cases (75%) had some form 
of IVC involvement. In two cases, level III and IV IVC throm-
bus were present, and in another case, dense desmoplastic 
adhesions with IVC were found along the entire length of the 
mass. In a retrospective study of eight patients done by Seth 
et al. (Table 2), 50% of the patients had IVC thrombus (14). 
They reported that the IVC thrombus in PNET was signifi-
cantly more friable than IVC thrombus of other renal malig-




Figure 3: Histopathology and immunohistochemistry of case 4. (a) Showing (Hematoxylin–Eosin staining) small uniform round 
cells with a hyperchromatic nucleus and mild to moderate pale staining cytoplasm and pseudo-rosettes (20×). (b) Small round 
cells CD-99 IHC positive (20×). (c) Small round cells, FLI-1 positive (20×).
of pulmonary thromboembolism. Renal tumors with IVC 
thrombus are inherently known to be aggressive biologically. 
Renal PNET should be suspected in young patients present-
ing with renal mass and IVC thrombus, and multimodality 
treatment should be offered, where proven.
Preoperative angioembolization may facilitate resection 
of large and more advanced stage tumors with comparably 
less blood loss to nephrectomy alone. We will consider it in 
selected future cases where suspicion of extensive neovascu-
larization is present.
Owing to nonspecific clinical and imaging features, renal 
PNET diagnosis is mainly based on histopathology and 
IHC, supported by the cytogenetic study. Renal PNET is 
characterized by small uniform round cells with dark nuclei, 
ill-defined cytoplasmic borders, and poorly formed rosette-
like structures. Presence of macrophage inhibitory cytokine 
(MIC-2) gene products, also known as CD99, 12E7, E2, 013, 
Renal primitive neuroectodermal tumor involving IVC
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Table 2: Review of literature for clinical presentation, and treatment and follow-up of renal PNET.










Age (years) 27.5 27 32 34 43 
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Table 2: Continued










Remission 03 (37.5%) 04 (25%)  01 (14.2%) 01 (25%) at  
2 years and  
4 months
Relapse 03 (42.8%) 07 (43.7%) 04 (57.1%) 08 (100%) 01 (25%) at  
8 months
Lost to follow-up 01 (14.2%) 01 (25%)
IVC, inferior vena cava; IHC, immunohistochemistry; PNET, primitive neuroectodermal tumor; LA, locally advanced; RN, radical  
nephrectomy; LND, Lymph node dissection; IVCT, IVC thrombectomy; NSE, neuron-specific enolase; CIK, cytokine-induced killer;  
DFS, disease-free survival; CD-99, cluster of differentiation-99.
and HBA71, suggest a PNET diagnosis (15) to renal PNET. 
CD99 is expressed strongly in almost all cases, although it is 
not specific for renal PNET (16). Besides, nearly two-thirds 
reveal FLI-1 expression (17). Although FLI-1 protein expres-
sion is seen not only in ES/PNET among small blue RCTs, it 
still can play a valuable adjunctive role in the diagnosis (18). 
Other markers, such as vimentin, cytokeratin, neuron-specific 
enolase, and S-100, have also been detected but they are not 
pathognomonic (19). On IHC, we consistently found CD-99 
in all cases and FLI-1 positivity in three (75%) of them.
As per cytogenetic studies, both PNET and Ewing’s sar-
coma are associated with translocation of the long arm of 
chromosomes 11 and 22, t [11, 22] [q22, q12] (19). Both are 
considered the end of a histological spectrum of “Ewing’s 
family of tumors” (EFT). The presence of EWSEwing’s sar-
coma (EWS) /FLI-1 fusion protein has a decisive and sup-
portive role in diagnosing PNET of the kidney.
The initial extent of disease at presentation is the essen-
tial factor while considering treatment. Radical nephrectomy 
is vital for local control of the disease. However, ES/PNET 
being an aggressive tumor often relapses even after complete 
resection. Adjuvant therapy in the form of chemotherapy 
and radiotherapy increases the chances of survival. The over-
all 5-year survival was less than 10% before the routine use 
of chemotherapy for Ewing’s family of tumors. Now survival 
of 45–55% is reported with multimodality treatment. PNET 
is treated with similar chemotherapy as Ewing’s sarcoma, as 
both belong to Ewing’s family of tumors. Earlier, the RCT 
II protocol was used for PNET, which included 2 mg/m2 
of vincristine, 75-mg/m2 bolus infusion of adriamycin, and 
1200 mg/m2 of cyclophosphamide (20). With the addition of 
etoposide and ifosfamide to the VAC regimen, the current 
standard chemotherapy protocol for PNET has been that for 
Ewing’s family of tumors. In the EFT-2001 protocol, 1800 
mg/m2 of ifosfamide per day for 5 days and 100 mg/m2 of 
etoposide per day for the same period are added to the VAC 
regimen (20).
Sun et al. studied the role of cytokine-induced killer (CIK) 
cell immunotherapy in a patient of renal PNET (10). They 
noted a survival advantage of 20 months with lesser adverse 
events with this form of therapy in comparison to chemo-
therapy. However, further research is needed to assess the 
usefulness of CIK cell immunotherapy and other targeted 
therapies for renal PNET.
In the study done by Thyavihally et al., 11 patients with 
surgical disease-free status had completed adjuvant treat-
ment. Four out of these were disease-free at the last fol-
low-up period, and a 5-year disease-free survival rate was 
36%. In a retrospective study conducted by Sun et al., four 
cases received adjuvant chemotherapy. They had a signifi-
cantly better overall survival of 36 months, compared with 
an overall survival of 10 months in the three patients with-
out adjuvant chemotherapy (10). In the present study, one 
of the patients with the localized disease received chemother-
apy, that is, VAC/IE of a total of 17 cycles and following up 
regularly with remission for the last 2 years and 4 months. 
However, another patient with locally advanced disease who 
refused for adjuvant treatment had a poor outcome with an 8 
months survival post-surgery. Thus, adjuvant therapy seems 
to play a vital role in the management of these cases and has 
a definitive survival advantage.
Even though the role of radiotherapy is not established 
in renal PNET, it may be useful in the presence of Gerota’s 
fascia involvement, positive surgical margins, and locally 
advanced disease. Kushner et al. from Memorial Sloan Ket-
tering Cancer Center presented a series of 54 cases of extra-
cranial PNETs, which revealed a disease-free survival of 24% 
at 2 years (21). The radiation dose in their study varied from 
5040 to 6000 rads. The uniform radiation therapy approach 
of Miser et al. has produced reasonable local control in 
PNET (22). They suggested that radiation therapy might be 
useful to ablate residual microscopic disease.
Renal PNET is presumed to be more aggressive than the 
PNET tumor of other locations in the body. It often recurs 
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locally and metastasizes early to the regional lymph nodes, 
lungs, liver, bone, and bone marrow, resulting in a poor prog-
nosis. Thyavihally et al. in their retrospective study demon-
strated median survival to be 40 months, with 3 years and 5 
years disease-free survival rate of 60% and 42%, respectively 
(20). The overall survival in patients who had localized dis-
ease was 60 months, compared to patients with infection at 
regional nodes or distant sites, in whom the survival was 15 
months. This study indicates a better chance of survival in 
localized cases. In a review done by Cuesta Alcalá et al., the 
mean survival was 10 months. Only three of the 26 subjects 
had a more prolonged survival: 60, 48, and 24 months (23). 
The 5-year disease-free survival rate for patients presenting 
with well-confined extra-skeletal PNET is around 45–55%, 
and cases with advanced disease at presentation have a 
median relapse-free survival of only 2 years (6).
In our series, the patient with localized disease received 
chemotherapy, that is, VAC/IE of a total of 17 cycles and fol-
lowing up regularly with remission for the last 2 years and 
4 months. Although statistical comparisons cannot be made 
due to the small number of cases in our study, we still believe 
that adjuvant therapy, in addition to radical surgery, has a 
significant role in survival.
This study is limited by a minimal number of cases, along 
with attrition and its retrospective nature. Nevertheless, we 
draw the following conclusion not just from our experience 
but also from the literature.
Conclusion
Renal PNET is a distinct clinical entity with aggressive 
behavior. It can even present as a renal pelvis tumor. Clini-
cal features and imaging findings are nonspecific. Hence, the 
preoperative diagnosis is challenging. Histopathology and 
IHC are necessary to diagnose renal PNET. It is an extraor-
dinarily rare disease. Therefore, no definitive treatment 
guidelines exist for the management. Radical nephrectomy, 
along with chemotherapy used for Ewing’s family of tumors, 
provides a definite survival advantage. We conclude that mul-
timodality treatment in the form of surgery, chemotherapy, 
and radiotherapy should be used for better results.
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